Shattuck Labs, Inc. (STTK) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US82024L1035

Price
4.85 USD
Market cap
493.94 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Shattuck Labs, Inc. financials

Fiscal year2025
Revenue1.00 m USD
Operating income-51.51 m USD
EBIT-51.51 m USD
Net income-48.81 m USD
Diluted EPS – continuing operations-0.70 USD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.